EYESHOT (EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian Coronary Care Units)

EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs Registry

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02015624

Acronym

EYESHOT

Enrollment

2597

Registered

2013-12-19

Start date

2013-12-31

Completion date

2014-03-31

Last updated

2021-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Keywords

Acute coronary syndromes, Intensive Care Unit

Brief summary

This register will evaluate the use of different antithrombotic therapies, combinations of different drugs routinely used during any stage of hospital admission, with their timing, dosage and mode of administration, in patients with a diagnosis of Acute Coronary Syndrome in the Italian Coronary Care Unit during a study period of three weeks

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All consecutive patients discharged with a diagnosis of Acute Coronary Syndrome ( Non ST elevation or ST Elevation) undergoing myocardial revascularization or conservative treatment , admitted to the Coronary Care Unit during the observation period established. * Age ≥ 18 years * Signed informed consent

Exclusion criteria

* Patients enrolled in clinical trials of intervention * Diagnosis of Acute Coronary Syndrome caused by confounding comorbidities (eg . Trauma or surgery after non- cardiac ) * Patients already enrolled in eyeshot from another center.

Design outcomes

Primary

Measure	Time frame
Antithrombotic drugs in patient undergoing percutaneous transluminal coronary angiography, coronary artery bypass graft or no coronary revascularization	Participants will be followed for the duration of hospital stay, an expected average period of 7 days

Secondary

Measure	Time frame
In-hospital ischemic and hemorrhagic events	Participants will be followed for the duration of hospital stay, an expected average period of 7 days

Countries

Italy

Outcome results